Modified weekly cisplatin-based chemotherapy is acceptable in postoperative concurrent chemoradiotherapy for locally advanced head and neck cancer

Hsueh-Ju Lu; Chao-Chun Yang; Ling-Wei Wang; Pen-Yuan Chu; Shyh-Kuan Tai; Ming-Huang Chen; Muh-Hwa Yang; Peter Mu-Hsin Chang

doi:10.1155/2015/307576

Modified weekly cisplatin-based chemotherapy is acceptable in postoperative concurrent chemoradiotherapy for locally advanced head and neck cancer

Biomed Res Int. 2015:2015:307576. doi: 10.1155/2015/307576. Epub 2015 Feb 22.

Authors

Hsueh-Ju Lu¹, Chao-Chun Yang², Ling-Wei Wang³, Pen-Yuan Chu⁴, Shyh-Kuan Tai⁴, Ming-Huang Chen⁵, Muh-Hwa Yang⁶, Peter Mu-Hsin Chang⁵

Affiliations

¹ Division of Hematology and Oncology, Show Chwan Memorial Hospital, Changhua, Taiwan ; Faculty of Medicine, National Yang Ming University, Taipei, Taiwan ; Program in Molecular Medicine, School of Life Sciences, National Yang-Ming University, Taipei, Taiwan.
² Faculty of Medicine, National Yang Ming University, Taipei, Taiwan ; Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan ; Department of Medicine,Taipei City Hospital,Yang-Ming Branch, Taipei, Taiwan.
³ Faculty of Medicine, National Yang Ming University, Taipei, Taiwan ; Department of Oncology Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
⁴ Faculty of Medicine, National Yang Ming University, Taipei, Taiwan ; Department of Otolaryngology, Taipei Veterans General Hospital, Taipei, Taiwan.
⁵ Faculty of Medicine, National Yang Ming University, Taipei, Taiwan ; Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan.
⁶ Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan ; Institute of Clinical Medicine, National Yang Ming University, Taipei, Taiwan.

Abstract

Background: Triweekly cisplatin-based postoperative concurrent chemoradiotherapy (CCRT) has high intolerance and toxicities in locally advanced head and neck cancer (LAHNC). We evaluated the effect of a modified weekly cisplatin-based chemotherapy in postoperative CCRT.

Methods: A total of 117 patients with LAHNC were enrolled between December 2007 and December 2012. Survival, compliance/adverse events, and independent prognostic factors were analyzed.

Results: Median follow-up time was 30.0 (3.1-73.0) months. Most patients completed the entire course of postoperative CCRT (radiotherapy ≥ 60 Gy, 94.9%; ≥ 6 times weekly chemotherapy, 75.2%). Only 17.1% patients required hospital admission. The most common adverse effect was grade 3/4 mucositis (28.2%). No patient died due to protocol-related adverse effects. Multivariate analysis revealed the following independent prognostic factors: oropharyngeal cancer, extracapsular spread, and total radiation dose. Two-year progression-free survival and overall survival rates were 70.9% and 79.5%, respectively.

Conclusion: Modified weekly cisplatin-based chemotherapy is an acceptable regimen in postoperative CCRT for LAHNC.

Publication types

Clinical Study
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antineoplastic Agents / therapeutic use*
Chemoradiotherapy / methods
Cisplatin / therapeutic use*
Disease-Free Survival
Female
Head and Neck Neoplasms / drug therapy*
Head and Neck Neoplasms / pathology
Head and Neck Neoplasms / therapy*
Humans
Male
Postoperative Period
Prognosis
Radiotherapy Dosage
Retrospective Studies
Survival Rate

Substances

Antineoplastic Agents
Cisplatin